News

Orphazyme Annual Report 2019 Presentation

Feb 20, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the Company will be hosting an investor call at which Chief Executive Officer, Kim Stratton, and Chief Financial Officer, Anders Vadsholt, will be presenting the Orphazyme Annual Report 2019. The presentation will be followed by a Q&A session.

Orphazyme annual report 2019 presentation

Major shareholder announcement

Feb 13, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of February 12, 2020 holds a total 1,161,561 shares in the Company, corresponding to 4.85% of the share capital and that Danske Bank as of February 12, 2020 controls 7.24% of the voting rights in the Company.

Major shareholder announcement

Major shareholder announcement

Feb 12, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Consonance Capman GP LLC that as of February 11, 2020, Consonance Capman GP LLC indirectly holds 1,900,000 shares and voting rights in Orphazyme, corresponding to 7.03% of the total share capital and voting rights of Orphazyme.

Major shareholder announcement

Orphazyme announces presentations at WORLDSymposium™

Feb 11, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces two presentations at the 16^th Annual WORLDSymposium™, Orlando, Florida, February 10-13, 2020. These presentations highlight data from the Company’s randomized double-blind, placebo-controlled phase 2/3 trial with investigational drug candidate, arimoclomol, in Niemann-Pick disease Type C (NPC), and include previously reported primary endpoint data, pre-specified and post-hoc subgroup analyses, safety, and supportive biomarker data. 

Orphazyme announces presentations at worldsymposium

Reporting of transactions in Orphazyme’s shares

Feb 11, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby notifies receipt of the attached information of transactions in Orphazyme’s shares by a person closely associated with a person discharging managerial responsibilities in Orphazyme pursuant to Article 19 of the Market Abuse Regulation.

Notification orpha pooling person closely associated ...

Transactions in Orphazymes shares

Major shareholder announcement

Feb 11, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby notifies receipt of the attached major shareholder notifications pursuant to Section 30 of the Danish Capital Markets Act.

Major shareholder letter to Orphazyme as novo holdings ...

Major shareholder letter to Orphazyme

Major shareholder announcement

Major shareholder announcement

Feb 11, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Danske Bank A/S that Danske Bank as of February 7, 2020 holds a total 1,109,876 shares in the Company, corresponding to 5.54% of the share capital and that Danske Bank as of February 7, 2020 controls 8.07% of the voting rights in the Company.

Major shareholder announcement

Orphazyme completes registration of share capital increases of an aggregated nominal value of DKK 7,032,937

Feb 11, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that the registration of share capital increases of an aggregated nominal value of DKK 7,032,937 has been completed.

Orphazyme completes registration of share capital

Announcement of treasury shares

Feb 7, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, hereby announces with reference to the completed offering of 7,032,937 new shares and existing shares in a directed issue and private placement as announced by company announcement no. 12/2020 on February 7, 2020 that Orphazyme as of today no longer holds any treasury shares.

Announcement of treasury shares

Orphazyme completes offering of 7,032,937 shares in a directed issue and private placement and raises approximately DKK 745,000,000 (EUR 100 million/USD 110 million)

Feb 7, 2020

Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the completion of an offering of 7,032,937 new shares and existing shares in a directed issue and private placement raising gross proceeds of approximately DKK 745,000,000.

Orphazyme completes offering of 7 032 937 shares